Coya to meet with FDA about a Phase 2 trial of COYA 302 for ALS

Genetic factors influencing ALS survival identified in Japanese study

Researchers have identified new genetic variants that might influence survival among sporadic amyotrophic lateral sclerosis (ALS) patients in Japan. Genetic analyses in more than 1,000 ALS patients uncovered that small changes in the FGF1, THSD7A, and LRP1 genes could affect patients’ prognosis. In patient-derived nerve cells, the identified variants led…

My ALS prognosis affects how I wrestle with making decisions

Decisions, decisions. When did making health decisions become so challenging for me? Well, it began after I was diagnosed with ALS. Scheduling annual health screens and medical treatments became complex decisions. Even purchasing a new pair of sneakers came with specific considerations. ALS has created a whole…

Neurologists frustrated with ALS treatments now on market: Study

While neurologists are frustrated with the treatments for amyotrophic lateral sclerosis (ALS) now on the market, they rapidly adopt new therapies that may delay disease progression for use among their patients with the neurodegenerative disorder. That’s according to Spherix Global Insights, a company providing market research and business…

On my birthday I had everything I wanted

A couple weeks ago, a friend asked me, “What are you going to do for your birthday?” “We’ll just have a family dinner and play games,” I said. “That’s all I want.” When my husband, Todd, and I were married, we might have gone on a weekend getaway or out…

MTPA to stop Phase 3 trial of approved Radicava ORS for ALS

Mitsubishi Tanabe Pharma America (MTPA), which had been testing a once-daily regimen of its oral therapy Radicava ORS (edaravone) for amyotrophic lateral sclerosis (ALS), announced that it is discontinuing the Phase 3b trial and its extension study. That decision comes after an interim analysis by an independent…